WHO’s Working for Health 2022–2030 Action Plan

By Staff Writer

February 6, 2023

Introduction:

Achieving universal health care (UHC) is a World Health Organisation (WHO) strategic priority, with the goal of 1 billion more people benefitting from universal health coverage by 2025. This publication on health and care workforce planning provides a rationale for the related actions of the Working for Health progression model.

The Need for Planning and Financing:

Planning and financing are integral to the efficient and cost-effective development of health and care workforce policies. Their importance is particularly evident in low- and middle-income countries (LMICs), where technical and institutional capacity to support planning and financing is often inadequate. In such strained economic environments, building this capacity is a priority.

The Working for Health Model:

The Working for Health progression model offers a pathway for countries facing critical workforce challenges to progressively optimise, build, and strengthen their workforce. The model focuses on three key themes: planning and financing, education and employment, and protection and performance.

The Current Context:

The COVID-19 pandemic has highlighted the need for effective planning and strategic financing in the health and care workforce. LMICs face challenges such as building labour market demand for health and care workers, mobilising sufficient and sustainable revenue, and attracting and retaining workers within the health system.

Policy Landscape:

The WHO Global Strategy presents a range of policy options to advance the health and care workforce agenda. These options emphasise the need to strengthen the integration and synergy of health workforce policy with broader development strategies.

Challenges:

The COVID-19 pandemic has had a devastating impact on economies worldwide. Financial resources allocated to health and care workforce are constrained by the economic crises facing many countries. In addition, many countries lack the technical and institutional capacity to translate evidence-based information into policy development and implementation.

Future Directions:

The challenges faced by the health and care workforce require strategic planning and financing. Investment in the health and care workforce is critical in emergency and disaster risk management, building the resilience of the health system to shocks and surges in demand.

Conclusion:

The health and care workforce is a vital component of the healthcare ecosystem. As such, it is essential to invest in strategic planning and financing to ensure its growth and sustainability. By doing so, we can ensure a resilient health system capable of meeting the needs of populations worldwide.

 

 

Reference url

Recent Posts

access to medicines
         

Quantifying EU Medicine Access Challenges

🔍 Are we creating a healthcare system that truly works for everyone?

Recent findings from EFPIA shed light on alarming inequities in access to medicines across Europe, showing that only 46% of approved drugs are available to patients this year. With significant delays affecting smaller markets and critical cancer treatments, this article explores the systemic barriers at play and innovative solutions proposed to ensure fair access.

Dive into the full article to uncover how we can collectively shape a more equitable healthcare landscape.

#SyenzaNews #healthcare #MarketAccess

UK Medicine Payment Rates
      

Revitalizing Innovation: The Impact of UK Medicine Payment Rates

💡 Are the UK’s medicine payment rates stifling innovation in life sciences?

Recent analysis reveals that the staggering 23.5% payment rate for pharmaceuticals is not just limiting NHS spending but also curtailing R&D investments, delaying new drug launches, and threatening workforce stability. If we can lower these rates to below 10%, we could unleash significant growth and restore the UK’s competitive edge in the global life sciences landscape.

Discover the critical insights and recommendations that could reshape the future of healthcare in the UK.

#SyenzaNews #healthcarepolicy #innovation

Blinatumomab benefit assessment
            

Blinatumomab Benefit Assessment for ALL and Health Economics

🚀 How does a groundbreaking therapy change the landscape of acute lymphoblastic leukemia treatment?

The recent benefit assessment of Blinatumomab by the German Federal Joint Committee reveals critical insights into its potential as a consolidation therapy for adults with Philadelphia chromosome-negative B-cell precursor ALL. With its orphan drug status promising automatic benefits, the article explores the implications of its high cost and economic impacts, shedding light on the balance needed between innovation and sustainability in healthcare.

Jump into the full analysis to understand how this could impact clinical practice and health economics.

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.